



World Health
Organization

GUIDELINES



CONSOLIDATED GUIDELINES ON
**PERSON-CENTRED
HIV PATIENT MONITORING
AND CASE SURVEILLANCE**

JUNE 2017

HIV STRATEGIC INFORMATION FOR IMPACT

CONSOLIDATED GUIDELINES ON
PERSON-CENTRED
HIV PATIENT MONITORING
AND CASE SURVEILLANCE

JUNE 2017

Consolidated guidelines on person-centred HIV patient monitoring and case surveillance
ISBN 978-92-4-151263-3

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

CONTENTS

Acknowledgements	vi
Abbreviations and acronyms	viii
Key definitions	x
1. Introduction	1
1.1 Context	2
1.2 Objectives of these guidelines	4
1.3 Guiding principles	5
1.4 Target audience	5
1.5 Methodology	6
1.6 Major recommendations in the guidelines	6
1.7 How to implement the guidance in this document	9
1.8 Learning from country experience	10
2. HIV patient monitoring	15
2.1 Introduction	17
2.2 Minimum dataset and key definitions for HIV patient monitoring	24
2.3 Standardized data collection and reporting tools	30
2.4 Integration and linkages	41
2.5 Global and national strategic information (SI) indicators covered by the patient monitoring system	59
2.6 Periodic review and use of data from the HIV patient monitoring system	67
2.7 Adaption and implementation of the HIV patient monitoring system	85
3. HIV case surveillance	97
3.1 Overview	99
3.2 Ethical principles and considerations	100
3.3 Reporting laws, regulations and policies	101
3.4 Reporting process and procedures	102
3.5 Surveillance system design and implementation	116
3.6 Analysis, interpretation and presentation of case surveillance data	122

4.	Using unique identifiers for person-centred monitoring of HIV services	135
4.1	Overview	137
4.2	Types of identifiers	138
4.3	Development path for unique identifiers	141
4.4	Attributes and security of a unique identifier system	151
4.5	System architecture and methods of unique identification	152
4.6	What to do next – “the how”	156
	References	158
	Appendix: Indicator instructions for HIV patient monitoring systems	162

List of web annexes

2. Patient monitoring

Annex 2.2.1	2017 HIV patient monitoring system minimum dataset
Annex 2.3.2	HIV care and treatment patient card
Annex 2.3.3	Community-based ART tool
Annex 2.3.4	HIV care/ART transfer or referral/counter-referral form
Annex 2.3.5	ART register
Annex 2.3.6a	HIV cross-sectional report
Annex 2.3.6b	ART cohort report
Annex 2.4.6	HIVDR EWI sampling, abstraction and reporting guidance
Annex 2.5	SI guide indicators with data sourced from the HIV patient monitoring system
Annex 2.6.2	Checklist for the rapid assessment of the patient monitoring system
Annex 2.7.6	Country example of patient monitoring tools – Western Cape, South Africa: integrated patient folder

3. HIV case surveillance

Annex 3.3	Example of HIV case surveillance reporting mandate
Annex 3.4.7	Model case report forms (adults, children)
Annex 3.4.12	Outcome measures and standards for performance of HIV case surveillance systems
Annex 3.5.2	Situational assessment for patient monitoring system, case surveillance and unique identifiers

Illustrative country examples

Table 1.2	Examples of country improvements to health information systems
Box 1.2	Integrated systems for routine collection of HIV patient data in Brazil
Box 2.27	A tiered approach to electronic patient records in South Africa
Box 2.28	Data standardization and simplification in South Africa
Annex 2.7.6	Example of integrated patient monitoring records from South Africa
Box 3.3	Using case surveillance data to target HIV prevention in Myanmar
Box 3.4	Using case surveillance data in Haiti
Box 4.1	Towards advanced use of patient identifiers in Thailand and Western Cape province, South Africa
Box 4.2	Using unique identifiers to scale up monitoring for pregnant women with HIV in India

ACKNOWLEDGEMENTS

The concepts and material presented in this publication were informed by three workshops organized with several countries and organizations in March, July and September 2016 around the three major topics that are presented in these guidelines. WHO acknowledges the contributions of the participants at these meetings, including staff of national AIDS programmes and experts in various fields related to HIV surveillance, patient monitoring and unique identifiers.

COUNTRY PARTICIPANTS

Tlthagiso **Pilatwe**, Ministry of Health and Wellness, Botswana; Ana Roberta **Pati Pascom**, Ministry of Health, Brazil; Levelet **Jean**, Ministry of Public Health and Population, Haiti; Bhavna **Sangal**, Ministry of Health and Family Welfare, India; Thokozani **Kalua**, Ministry of Health, Malawi; Htun Nyunt **Oo**, Ministry of Health and Sports, Myanmar; Joseph **Nondi**, Ministry of Health and Social Welfare, Tanzania; Yongjua **Laosiritaworn**, Ministry of Public Health, Thailand; Nyambe **Sinyange**, Ministry of Health, Zambia; Mutsa **Mhangara**, Ministry of Health and Child Welfare, Zimbabwe

CIVIL SOCIETY

Diane **Amanyire**, Uganda; Paul **Biondich**, United States of America (USA); Dave **Burrows**, Australia; Fernando **Cano**, Guatemala; Sungai **Chabata**, Zimbabwe; Shaun J. **Grannis**, USA; Tapiwa **Kujinga**, Zimbabwe; Lilian **Mwokero**, Uganda; Noma **Rangana**, South Africa; Rob **Rohlin**, USA; Kenly **Sikwese**, Zambia; Stephen **Watiti**, Uganda

DONORS / PARTNER ORGANIZATIONS

Jacob **Dee**, Steve **Gutreuter**, Joseph **Nadji**, Sriyanjit **Perera**, Valerie **Pelletier**, Italia **Rolle**, Xen **Santas**, Amitabh **Suthar**, Mahesh **Swaminathan**, Linda **Wright-Deageuro** – Centers for Disease Control and Prevention (USA); UNAIDS staff; Jinkou **Zhao**, Mauro **Guaraineri**, Ed **Ngoskin** – Global Fund to Fight AIDS, Tuberculosis and Malaria; Priscilla **Idele**, Lori **Thorell** – United Nations Children’s Fund (UNICEF); Sandy **Schwarzc** – University of California, San Francisco (UCSF); Katherine **Hildebrand** – University of Cape Town, South Africa; Olga **Varetska** – AIDS Alliance; Whitney **Ewing**, Sharon **Weir** – University of North Carolina, USA; Ruth **Macklin**, Stefan **Baral** – Johns Hopkins University (JHU), USA; Calum **Davery** – London

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26405

